Published in Immunol Cell Biol on December 05, 2006
Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med (2009) 3.94
IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood (2009) 3.14
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol (2007) 2.19
Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood (2011) 1.70
Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome. Biomark Med (2008) 1.55
Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol (2013) 1.14
APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS (2010) 1.08
Increased level of arginase activity correlates with disease severity in HIV-seropositive patients. J Infect Dis (2010) 1.05
Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. Curr Opin HIV AIDS (2008) 1.00
Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection. PLoS Negl Trop Dis (2013) 0.99
XVII International AIDS Conference: From Evidence to Action - Basic science. J Int AIDS Soc (2009) 0.86
T cell-, interleukin-12-, and gamma interferon-driven viral clearance in measles virus-infected brain tissue. J Virol (2011) 0.84
Loss of CD127 & increased immunosenescence of T cell subsets in HIV infected individuals. Indian J Med Res (2011) 0.83
Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy. Immunotherapy (2011) 0.80
R5-SHIV induces multiple defects in T cell function during early infection of rhesus macaques including accumulation of T reg cells in lymph nodes. PLoS One (2011) 0.80
Expression of interleukin-15 and interleukin-15Rα in monocytes of HIV type 1-infected patients with different courses of disease progression. AIDS Res Hum Retroviruses (2011) 0.79
Comparison of the specificities of IgG, IgG-subclass, IgA and IgM reactivities in African and European HIV-infected individuals with an HIV-1 clade C proteome-based array. PLoS One (2015) 0.79
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis (1999) 1.70
Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis (1998) 1.41
Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape. Stem Cells (2000) 1.38
Transmission of triple-class, drug-resistant HIV-1 in Australia. Intern Med J (2010) 1.37
Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS (2000) 1.03
Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J Immunol Methods (2012) 0.92
Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling. AIDS Res Hum Retroviruses (2001) 0.87
Anal intraepithelial neoplasia and squamous cell carcinoma in HIV-infected adults. HIV Med (2013) 0.87
A model of primary HIV-1 infection. Math Biosci (1998) 0.82
Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. Hum Vaccin (2007) 0.82
Intractable headache as the presenting complaint of AIDS-related lymphoma confined to bone. J Acquir Immune Defic Syndr (1994) 0.81
Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects. Hum Vaccin (2005) 0.80
Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy. Clin Exp Immunol (2008) 0.80
Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay. Pathology (2015) 0.77
Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses (1999) 0.75
Managing HIV. Part 1: Principles. 1.2 Strategies of care in managing HIV. Med J Aust (1996) 0.75